Faculty

Faculty

Stacey A Cohen

MD

Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington

Professor

Faculty

Arvind Dasari

MD, MS

The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Department of Gastrointestinal Medical Oncology

Moderator

Tanios Bekaii-Saab

MD

Mayo Clinic in Arizona, Phoenix, Arizona

David F and Margaret T Grohne Professor of Novel Therapeutics for Cancer Research I, Chair and Consultant, Division of Hematology and Medical Oncology

Mayo Clinic College of Medicine and Science, Phoenix, Arizona

Professor

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:00 PM — Educational Meeting

MODULE 1: Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High (MSI-H)/Mismatch Repair-Deficient (dMMR) Localized and Locally Advanced Colorectal Cancer (CRC)

• Current role of neoadjuvant and adjuvant systemic treatment for localized/locally advanced rectal and colon tumors; historical outcomes achieved with chemotherapy and chemoradiation therapy for patients with MSI-H/dMMR disease
• Updated results with dostarlimab as an alternative to surgery for MSI-H/dMMR locally advanced rectal cancer; implications for organ preservation
• FDA breakthrough therapy designation for dostarlimab for patients with locally advanced MSI-H/dMMR rectal cancer; ongoing evaluation in the registrational Phase II AZUR-1 trial
• Early-phase data with neoadjuvant anti-PD-1/PD-L1 antibodies alone or in combination with other immunotherapies for patients with nonmetastatic MSI-H/dMMR colon cancer; ongoing Phase III AZUR-2 study of perioperative dostarlimab in this population
• Design, eligibility criteria and key efficacy and safety findings from the Phase III Alliance A021502/ATOMIC trial assessing atezolizumab in combination with mFOLFOX6 and continued as monotherapy in the adjuvant setting for patients with Stage III CRC and dMMR tumors
• Potential role of adjuvant atezolizumab for patients with Stage III dMMR CRC
• Biological rationale for and ongoing studies investigating immune checkpoint inhibition for localized microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) CRC 

MODULE 2: Clinical Relevance and Practical Use of Molecular Residual Disease (MRD) Analysis in CRC

• Biological rationale for circulating tumor DNA (ctDNA)-based MRD monitoring in CRC; benefits of ctDNA monitoring over traditional means of follow-up
• Published datasets (eg, the CIRCULATE-Japan and BESPOKE CRC trials) evaluating the use of ctDNA testing to identify patients at increased risk of recurrence
• Recent findings from various studies (eg, the DYNAMIC, CALGB/SWOG-80702 and ALTAIR trials) attempting to validate the use of ctDNA testing in predicting benefit from adjuvant treatment regimens
• Ongoing Phase III trials examining the clinical utility of ctDNA-based MRD testing for guiding treatment decision-making in localized CRC
• Available evidence supporting the use of ctDNA as a tool for monitoring for recurrence after curative-intent therapy; recommended timing and frequency of ctDNA testing in the surveillance setting
• Current and potential future role of ctDNA testing in localized, locally advanced and metastatic CRC

MODULE 3: Recent Advances in Metastatic CRC (mCRC) — Optimizing Immunotherapy and Other Approaches

• Rationale for the evaluation of dual immune checkpoint inhibition for newly diagnosed mCRC
• Key efficacy and safety findings from the CheckMate 8HW trial assessing nivolumab/ipilimumab versus chemotherapy with or without bevacizumab or cetuximab for previously untreated MSI-H/dMMR mCRC; FDA approval and current role of nivolumab/ipilimumab in first-line therapy
• Early data with immune checkpoint inhibitors alone and in combination with other agents for patients with MSS/pMMR mCRC
• Mechanistic similarities and differences between zanzalintinib and other multikinase inhibitors for CRC; rationale for combining zanzalintinib with an anti-PD-1/PD-L1 antibody in therapy for mCRC
• Recently presented efficacy and safety findings from the Phase III STELLAR-303 trial evaluating zanzalintinib with atezolizumab for pretreated MSS/pMMR mCRC; implications for therapeutic sequencing
• Future development plans for zanzalintinib/atezolizumab in the management of CRC
• Available data with and optimal use of targeted therapy for patients with mCRC and a BRAF, HER2 or KRAS G12C mutation

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal cancer (CRC).

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand validated biomarkers of response (eg, RAS mutations, microsatellite instability [MSI]/mismatch repair [MMR] deficiency, HER2 overexpression, BRAF V600E mutations, KRAS G12C mutations) found in patients with CRC, and consider the implications for molecular testing and clinical care.
• Evaluate the biological rationale for the use of immune checkpoint inhibitors in the management of MSI-high (MSI-H)/MMR-deficient (dMMR) localized and advanced CRC, and counsel patients regarding evidence-based and guideline-endorsed treatment recommendations.
• Optimize the current and future use of neoadjuvant and adjuvant therapy for patients with localized and locally advanced CRC, considering the influence of various clinical and biological factors such as MSI-H/dMMR status.
• Recognize the clinical relevance of circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker in CRC, and comprehend the rationale for its use in detecting molecular residual disease.
• Appreciate published datasets documenting the clinical utility of ctDNA testing in risk stratification, surveillance and treatment decision-making for patients with CRC, and consider the current and future role of this strategy in personalizing therapeutic recommendations.
• Formulate a plan to guide the selection and sequencing of therapies for patients diagnosed with metastatic CRC (mCRC) accounting for tumor sidedness, biomarker profile, prior systemic therapy, symptomatology and personal goals of treatment.
• Appreciate published research documenting the efficacy of targeted therapeutic approaches for patients with mCRC and various actionable genomic alterations in order to personalize treatment recommendations.
• Recall ongoing trials evaluating novel agents and strategies for patients with mCRC, and use this information to refer candidates for study participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Andrea Cercek, MD (PowerPoint Slides) — Advisory Boards: 3T Biosciences, AbbVie Inc, Agents, Amgen Inc, Daiichi Sankyo Inc, GSK, Janssen Biotech Inc, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Summit Therapeutics, UroGen Pharma; Contracted Research: GSK, Pfizer Inc. Dr Cohen — Advisory Committees: AbbVie Inc, Blueprint Medicines, Boston Scientific Corporation, Caris Life Sciences, DoMore Diagnostics, Exact Sciences Corporation, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: GSK. Dr Dasari — Advisory Committees: Agenus Inc, Bristol Myers Squibb, Exelixis Inc, Illumina, Lantheus, Personalis, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Crinetics Pharmaceuticals, Eisai Inc, Enterome, Guardant Health, Hutchison MediPharma, Natera Inc, NeoGenomics, Personalis, RayzeBio, Taiho Oncology Inc, Xencor.

CONTRIBUTING CLINICAL INVESTIGATORS
Marwan Fakih, MD — Advisory Committees: Genentech, a member of the Roche Group, Janssen Research and Development, Merus, Mirati Therapeutics Inc, Tempus, Xilio Therapeutics; Consulting Agreements: AbbVie Inc, Adagene, Bristol Myers Squibb, Delcath Systems Inc, Iterion Therapeutics, Merck, Microbial Machines, Mirati Therapeutics Inc, Revolution Medicines, Summit Therapeutics, Taiho Oncology Inc, Totus Medicines; Contracted Research: Agenus Inc. Christopher Lieu, MD — Consulting Agreements: Pfizer Inc; Contracted Research: Genentech, a member of the Roche Group, Janssen Biotech Inc. Anwaar Saeed, MD — Advisory Committees and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Autem Therapeutics, BeOne, Bristol Myers Squibb, Exact Sciences Corporation, Exelixis Inc, KAHR Medical, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc, Replimune, Taiho Oncology Inc, Xilio Therapeutics; Contracted Research: Actuate Therapeutics, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Coherus BioSciences, Exelixis Inc, Henlius, Incyte Corporation, KAHR Medical, Merck, Oxford BioTherapeutics, Phanes Therapeutics Inc, Regeneron Pharmaceuticals Inc, Replimune; Data and Safety Monitoring Boards/Committees: Arcus Biosciences.

MODERATOR
Dr Bekaii-Saab — Consulting Agreements (to Institution): Arcus Biosciences, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merck KGaA, Merus, Pfizer Inc, Revolution Medicines Inc, Seagen Inc, Servier Pharmaceuticals LLC; Consulting Agreements (to Self): AbbVie Inc, Aptitude Health, Arsenal Biosciences Inc, AstraZeneca Pharmaceuticals LP, BeOne, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, Exact Sciences Corporation, Exelixis Inc, Foundation Medicine, GSK, Illumina, Janssen Biotech Inc, Kanaph Therapeutics, Lisata Therapeutics, Natera Inc, Ryght AI, Sanofi, Sobi, Stemline Therapeutics Inc, Takeda Pharmaceuticals USA Inc, Treos Bio, Xilio Therapeutics, Zai Lab; Data and Safety Monitoring Boards/Committees: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, FibroGen Inc, Merck, Suzhou Kintor; Inventions/Patents: WO/2018/183488 — Human PD-1 peptide vaccines and uses thereof, licensed to Imugene, WO/2019/055687 — Methods and compositions for the treatment of cancer cachexia, licensed to Recursion; Research Funding (to Institution): Agios Pharmaceuticals Inc, AltruBio, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merus, Mirati Therapeutics Inc, Novartis, Pfizer Inc, pharmaand GmbH, Revolution Medicines Inc, Seagen Inc, Sumitomo Pharma America; Scientific Advisory Boards: Artiva Biotherapeutics Inc, Immuneering Corporation, Imugene, Replimune, Sun Biopharma, Xilis; Nonrelevant Financial Relationships: MJH Life Sciences, Pancreatic Cancer Action Network, The Valley Hospital, UpToDate.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Exelixis Inc, GSK, and Natera Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:00 PM on Friday, May 29th. If you are interested in attending, please visit the registration desk outside Continental Room C (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).
Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Faculty

Faculty

Professor Giuseppe Curigliano

MD, PhD

University of Milano European Institute of Oncology, Milano, Italy

Clinical Director, Division of Early Drug Development for Innovative Therapy, Co-Chair, Cancer Experimental Therapeutics Program, Department of Oncology and Hemato-Oncology

Faculty

Rebecca A Dent

MD, MSc

National Cancer Centre Singapore, Singapore

Senior Consultant, Division of Medical Oncology

Duke-NUS Medical School, Singapore

Professor

Faculty

Erika Hamilton

MD

Sarah Cannon Research Institute, SCRI Oncology Partners, Nashville, Tennessee

Chief Development Officer, Late Phase, Director, Breast Cancer Research Program

Moderator

Hope S Rugo

MD

City of Hope Comprehensive Cancer Center, Duarte, California

Director, Women’s Cancers Program, Division Chief, Breast Medical Oncology, Professor, Department of Medical Oncology and Therapeutics Research

UCSF

Professor Emeritus

Faculty

Nadia Harbeck

MD, PhD

LMU University Hospital, Munich, Germany

Breast Center Director, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer (mTNBC)

• Scientific rationale for investigating TROP2-directed ADCs for previously untreated mTNBC
• Key efficacy and safety data from the Phase III ASCENT-04/KEYNOTE-D19 and ASCENT-03 trials evaluating sacituzumab govitecan in combination with pembrolizumab and as monotherapy for patients with previously untreated PD-L1-positive and PD-L1-negative mTNBC, respectively
• Published data from the Phase III TROPION-Breast02 study of first-line datopotamab deruxtecan (Dato-DXd) versus chemotherapy for patients with advanced TNBC for whom immunotherapy was not an option
• Recent FDA approval of Dato-DXd for patients with previously untreated mTNBC who are not candidates for PD-1/PD-L1 inhibitor therapy; current clinical utility of this strategy and potential role of sacituzumab govitecan in the up-front setting 
• Updated data with trastuzumab deruxtecan (T-DXd) in the subset of patients with previously treated hormone receptor (HR)-negative, HER2-low advanced breast cancer in the Phase III DESTINY-Breast04 study; current role alongside other treatment options
• Clinical trial findings with and ongoing investigation of other ADCs for mTNBC, such as sacituzumab tirumotecan and izalontamab brengitecan

MODULE 2: Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC)

• Historical outcomes with standard HER2-targeted therapies for newly diagnosed HER2-positive mBC; rationale for the evaluation of HER2-targeted ADCs in the front-line setting
• Published efficacy and safety findings from the Phase III DESTINY-Breast09 trial documenting the benefit of T-DXd/pertuzumab versus taxane/trastuzumab/pertuzumab as first-line therapy for HER2-positive mBC
• Implications of the DESTINY-Breast09 trial for sequencing therapies for HER2-positive mBC
• Intracranial efficacy documented with T-DXd in published clinical trials, including DESTINY-Breast01, 02 and 03, DESTINY-Breast12, DEBBRAH and TUXEDO-1; implications for the management of HER2-positive mBC
• Outcomes documented among patients with previously treated HER2-positive mBC without CNS involvement in pivotal clinical studies of T-DXd
• Other promising HER2-directed ADCs under investigation for HER2-positive mBC

MODULE 3: Role of ADCs in the Management of Endocrine-Resistant HR-Positive mBC

• Long-term efficacy and safety findings from the Phase III TROPiCS-02 trial of sacituzumab govitecan for previously treated HR-positive, HER2-negative mBC
• Optimal integration of sacituzumab govitecan into management algorithms for HR-positive, HER2-negative disease
• Available efficacy and safety findings from the Phase III TROPION-Breast01 study of Dato-DXd versus investigator’s choice of chemotherapy for pretreated HR-positive, HER2-negative mBC
• FDA approval of Dato-DXd for patients with HR-positive, HER2-negative mBC who have previously received endocrine-based therapy and chemotherapy; current clinical role
• Available data from the DESTINY-Breast04 and DESTINY-Breast06 studies evaluating T-DXd versus chemotherapy for patients with previously treated HER2-low and HER2-ultralow advanced breast cancer
• FDA approval of T-DXd for advanced HR-positive, HER2-low and HER2-ultralow breast cancer progressing after one or more endocrine therapies in the metastatic setting; optimal incorporation into disease management

MODULE 4: Utility of ADCs for Localized Breast Cancer

• Key clinical factors in the selection of neoadjuvant and adjuvant systemic therapy for patients with HER2-positive localized breast cancer; effect of various therapeutic approaches on outcomes
• Published findings from the Phase III DESTINY-Breast11 study evaluating T-DXd as a component of neoadjuvant therapy for patients with high-risk, HER2-positive localized breast cancer
• Recently presented data from the Phase III DESTINY-Breast05 study of T-DXd versus T-DM1 for patients with high-risk HER2-positive breast cancer and residual invasive disease after neoadjuvant therapy
• Recent FDA approval of T-DXd in the neoadjuvant and adjuvant settings; selection of appropriate candidates with HER2-positive localized breast cancer for these strategies 
• Ongoing Phase III trials, such as ASCENT-05, ADAPT-TN-III, ADAPT-TN-IV, TROPION-Breast04, TROPION-Breast05, TroFuse-012 and TroFuse-032, evaluating TROP2 ADCs as a component of neoadjuvant or adjuvant therapy for localized disease; estimated completion dates

MODULE 5: Tolerability Considerations with ADCs for Breast Cancer

• Spectrum, incidence and severity of common and unique adverse events (AEs) with different ADCs employed in the management of breast cancer
• Monitoring and management of acute “chemotherapy-like” AEs reported with ADCs, such as cytopenias and gastrointestinal events
• Recommended algorithms for mitigating more serious (eg, interstitial lung disease, left ventricular dysfunction) or unique (eg, oral mucositis/stomatitis, ocular AEs) toxicities documented with one or more ADCs
• Strategies to distinguish the cause of AEs that could be attributable to either agent in ADC-containing combination regimens
• Impact on tolerability, if any, of the placement of ADCs in the treatment course (eg, later-line therapy for metastatic disease, first-line therapy for metastatic disease or neoadjuvant/adjuvant therapy)

Target Audience
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, general and breast surgeons and other healthcare providers involved in the treatment of breast cancer.

Learning Objectives
At the conclusion of this activity, participants should be able to

• Assess available Phase III data with HER2-directed antibody-drug conjugate (ADC) therapy as a component of neoadjuvant therapy for patients with high-risk localized breast cancer, and consider the current clinical role of this novel treatment approach.
• Evaluate current research evidence with HER2-directed ADC therapy for patients with HER2-positive localized breast cancer and residual disease after neoadjuvant treatment.
• Appraise available research data and relevant clinical and biological factors guiding the selection of first-line therapy for patients with newly diagnosed HER2-positive metastatic breast cancer (mBC).
• Review published research supporting TROP2-directed ADC therapy in combination with anti-PD-1/PD-L1 antibodies for triple-negative mBC, and use this information to make appropriate treatment recommendations.
• Evaluate published clinical research findings with TROP2-directed ADC monotherapy for HR-positive and triple-negative mBC, and optimally incorporate these agents into clinical care.
• Assess the biological rationale for the evaluation of HER2-directed ADCs for HER2-low and HER2-ultralow mBC, and identify patients appropriate for this treatment approach.
• Discern the side effects and toxicities associated with FDA-approved ADCs in the care of patients with breast cancer, and identify strategies to manage and mitigate these complications.
• Recall ongoing trials evaluating the potential role of novel ADC-based strategies in the localized and metastatic settings, and appropriately counsel patients with breast cancer regarding enrollment.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Curigliano — Advisory Committees, Consulting Agreements and Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Roche Laboratories Inc. Prof Dent — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Lilly, MSD, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc. Dr Hamilton — Consulting/Advisory Roles (All Payments to Institution): Accutar Biotechnology Inc, Arvinas, AstraZeneca Pharmaceuticals LP, BeOne, Circle Pharma, Daiichi Sankyo Inc, Entos Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, Halda Therapeutics, Incyclix Bio, IQVIA, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Jefferies LLC, Johnson & Johnson, Lilly, Medical Pharma Services SRO, Mersana Therapeutics Inc, Novartis, Pfizer Inc, Pyxis Oncology, Samsung Bioepis, Shorla Oncology, Stemline Therapeutics Inc, Tempus, Zentalis Pharmaceuticals; Research Funding (All Payments to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Accutar Biotechnology Inc, ADC Therapeutics, Akesobio Australia Pty Ltd, Amgen Inc, Aravive Inc, ARS Pharmaceuticals, Artios Pharma Limited, Arvinas, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, BeOne, Black Diamond Therapeutics Inc, Bliss Biopharmaceutical (Hangzhou) Co Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Compugen, Context Therapeutics, Cullinan Therapeutics, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Duality Biologics, eFFECTOR Therapeutics Inc, Eisai Inc, Ellipses Pharma, Elucida Oncology Inc, EMD Serono Inc, Fochon Pharmaceuticals, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Inspirna, InventisBio, Jacobio Pharmaceuticals Group Co Ltd, Karyopharm Therapeutics, K-Group Beta, Kind Pharmaceuticals LLC, Leap Therapeutics Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Merus, Molecular Templates, Myriad Genetic Laboratories Inc, Novartis, NuCana, Olema Oncology, Oncothyreon, ORIC Pharmaceuticals, Orinove Inc, Orum Therapeutics, Pfizer Inc, pharmaand GmbH, PharmaMar, Pieris Pharmaceuticals Inc, Pionyr Immunotherapeutics, Plexxikon Inc, Prelude Therapeutics, ProFound Therapeutics, Radius Health Inc, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Repertoire Immune Medicines, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Stemline Therapeutics Inc, Sutro Biopharma, Syndax Pharmaceuticals, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tolmar, Transcenta, Treadwell Therapeutics, Verastem Inc, Zenith Epigenetics, Zymeworks Inc; Nonrelevant Financial Relationships: Dana-Farber Cancer Institute. Prof Harbeck — Consulting Agreements: Exact Sciences Corporation, Sandoz Inc, a Novartis Division; Data and Safety Monitoring Boards/Committees: Gilead Sciences Inc, IQVIA, Roche Laboratories Inc; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Group, MSD, Novartis, Pfizer Inc, Pierre Fabre, Roche Laboratories Inc, Stemline Therapeutics Inc, Viatris, Zuellig Pharma; Nonrelevant Financial Relationships: West German Study Group (WSG).

MODERATOR
Dr Rugo — Advisory Committees and Consulting Agreements: BioNTech SE, Bristol Myers Squibb, Helsinn Therapeutics (US) Inc, Napo Pharmaceuticals; Contracted Research (Funding to City of Hope): Bicycle Therapeutics, Genentech, a member of the Roche Group, Merck, Stemline Therapeutics Inc; Contracted Research (Funding to Prior Institution, UCSF): Ambrx, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room A (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:30 PM on Monday, June 1st. If you are interested in attending, please visit the registration desk outside Continental Room A (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Faculty

Faculty

Joshua Brody

MD

The Tisch Cancer Institute at Mount Sinai, New York, New York

Director, Lymphoma Immunotherapy Program

Icahn School of Medicine at Mount Sinai, New York, New York

Faculty Member, Icahn Genomics Institute

Faculty

Manali Kamdar

MD, MBBS

University of Colorado Cancer Center, Aurora, Colorado

Associate Professor, Clinical Director of Lymphoma Services, Morton and Sandra Saffer Endowed Chair in Hematology Research, Division of Hematology, Hematologic Malignancies

Faculty

Tycel Phillips

MD, FASCO

City of Hope Comprehensive Cancer Center, Duarte, California

Associate Professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation

Moderator

Jeremy S Abramson

MD, MMSc

Massachusetts General Hospital, Boston, Massachusetts

Director, Center for Lymphoma

Harvard Medical School, Boston, Massachusetts

Professor of Medicine

Faculty

Jason Westin

MD, MS, FACP, FASCO

The University of Texas MD Anderson Cancer Center, Houston, Texas

Director, Lymphoma Clinical Research, Section Chief, Aggressive Lymphoma, Professor, Department of Lymphoma and Myeloma

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL)

• Factors such as patient age, performance status, comorbidities or prior therapies influencing eligibility for CAR T-cell therapy
• Long-term efficacy and safety data with axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tis-cel) and lisocabtagene maraleucel (liso-cel) for multiregimen-relapsed DLBCL
• Major findings from Phase III studies with CAR T-cell therapy as second-line treatment for DLBCL
• FDA approvals of axi-cel and liso-cel as second-line therapy and appropriate identification of candidates for this strategy
• Rationale for, preliminary results with and ongoing assessment of CAR T-cell therapy in the up-front setting for high-risk disease
• Early results with and ongoing investigation of other CAR T-cell platforms for DLBCL (eg, rapcabtagene autoleucel)

MODULE 2: Bispecific Antibody Therapy for DLBCL

• Pharmacologic similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies for non-Hodgkin lymphoma (NHL)
• Key efficacy and safety outcomes from pivotal studies of glofitamab and epcoritamab monotherapy for relapsed/refractory (R/R) DLBCL
• Emerging outcomes from the Phase III EPCORE DLBCL-1 trial of epcoritamab monotherapy versus investigator’s choice of chemotherapy for R/R DLBCL 
• FDA approvals of glofitamab and epcoritamab; evidence-based sequencing of and selection between these agents for R/R DLBCL
• Available Phase III findings with bispecific antibodies in combination with other anticancer therapies and in earlier settings for DLBCL, including those from the STARGLO and SUNMO studies
• Early data with and ongoing assessment of other bispecific antibody-containing combination strategies for DLBCL

MODULE 3: CAR T-Cell Therapy for Other Lymphoma Subtypes

• Extended follow-up with axi-cel, tis-cel and liso-cel for multiregimen-relapsed follicular lymphoma (FL); appropriate selection of candidates with FL for CAR T-cell therapy
• Outcomes from the high-risk second-line subgroup of the Phase II TRANSCEND FL study of liso-cel for R/R FL; implications, if any, for therapeutic sequencing
• Ongoing and planned trials (eg, ZUMA-22, LEDA, TRANSFORM FL) of CAR T-cell therapy for R/R FL
• Key clinical research findings with brexucabtagene autoleucel and liso-cel for R/R mantle cell lymphoma (MCL)
• Optimal integration of CAR T-cell therapy into current MCL treatment algorithms
• Published results with liso-cel for R/R marginal zone lymphoma (MZL); recent FDA approval and current clinical role

MODULE 4: Bispecific Antibody Therapy for FL and Other Lymphoma Subtypes

• Available data establishing the efficacy and safety of mosunetuzumab and epcoritamab monotherapy for R/R FL
• Published outcomes from the Phase III EPCORE FL-1 study of epcoritamab in combination with lenalidomide/rituximab (R²) for patients with R/R FL
• Selection of appropriate candidates with FL to receive mosunetuzumab monotherapy, epcoritamab monotherapy and epcoritamab/R²; optimal incorporation opposite other available treatment options 
• Available research findings with bispecific antibody-based combination regimens beyond epcoritamab/R² for FL, including those from the US extension cohort of the Phase III CELESTIMO trial  
• Available data with, ongoing investigation of and potential clinical role of bispecific antibodies for other NHL subtypes (eg, mantle cell lymphoma, marginal zone lymphoma)

MODULE 5: Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies

• Comparative frequency and severity of cytokine release syndrome (CRS) and neurotoxicity/immune effector cell-associated neurotoxicity syndrome (ICANS) with available anti-CD19 CAR T-cell constructs for various NHL subtypes
• Guideline-endorsed approaches for the mitigation, monitoring and management of CRS and neurotoxicity/ICANS; role of corticosteroids, tocilizumab and other supportive care interventions
• Rationale for and potential implications of the recent elimination of the Risk Evaluation and Mitigation Strategy for patients receiving CAR T-cell therapy
• Long-term tolerability and toxicity considerations (eg, delayed neurotoxicity, cytopenias, hypogammaglobulinemia, infection, secondary malignancy) with CAR T-cell therapy
• Incidence, severity and time course of CRS and neurotoxicity/ICANS with bispecific antibody therapy for NHL
• Other tolerability concerns with bispecific antibodies for NHL; recommended mitigation and management protocols

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Develop an understanding of the biological rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with various forms of non-Hodgkin lymphoma (NHL).
• Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies for patients with various forms of NHL, and assess the similarities and differences among currently available agents in this class.
• Evaluate the available clinical research database with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies in the management of relapsed/refractory diffuse large B-cell lymphoma, and optimally incorporate these approaches into current treatment algorithms.
• Assess available research findings with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies for other B-cell lymphomas, including follicular lymphoma and mantle cell lymphoma, and identify patients for whom these novel approaches should be considered or recommended.
• Recognize adverse events associated with available and investigational CAR T-cell therapies and bispecific antibodies, and implement strategies to educate patients and manage complications.
• Recall ongoing research attempting to further define the optimal role of CAR T-cell therapy and bispecific antibody-based strategies for NHL, and counsel patients about potential clinical trial participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — Dr Brody has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Kamdar — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group. Dr Phillips — Advisory Boards/Consulting: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Caribou Biosciences Inc, Celgene Corporation, Genentech, a member of the Roche Group, Genetics Pharmaceuticals, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Johnson & Johnson, Kite, A Gilead Company, Lilly, Merck, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Xencor; Advisory Committees: BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Merck; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, Sobi; Data and Safety Monitoring Boards/Committees: Xencor; Nonrelevant Financial Relationships: Blood Cancer United. Dr Westin — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Faeth Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Ottimo Pharma, Pfizer Inc, pharmaand GmbH, PMV Pharma, Seagen Inc, Verastem Inc, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Verastem Inc, Zentalis Pharmaceuticals.

MODERATOR
Dr Abramson — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Miltenyi Biotec, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and Genmab US Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:30 PM on Sunday, May 31st. If you are interested in attending, please visit the registration desk outside Continental Room C (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Faculty

Faculty

Floor J Backes

MD

The Ohio State University College of Medicine, The James Cancer Hospital and Solove Research Institute, Columbus, Ohio

Professor, Larry J Copeland Professorship in Gynecologic Oncology, Director of Clinical Research, Associate Fellowship Director, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology

Faculty

Brian M Slomovitz

MD

Mount Sinai Medical Center, Miami, Florida

Professor, OB-GYN, Florida International University, Director, Gynecologic Oncology, Co-Chair, Cancer Research Committee

Moderator

Shannon N Westin

MD, MPH, FASCO, FACOG

The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Medical Director, Gynecologic Oncology Center, Director, Early Drug Development, Department of Gynecologic Oncology and Reproductive Medicine

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 8:30 PM — Educational Meeting

MODULE 1: Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC)

• Histologic subtypes and major molecular subgroups of EC; implications for prognosis and therapeutic decision-making
• Optimal approaches to biomarker testing for patients with newly diagnosed advanced EC; implications of biomarker status for treatment decision-making
• Similarities and differences in the designs and enrolled populations of the Phase III RUBY, NRG-GY018 and DUO-E trials evaluating the addition of dostarlimab, pembrolizumab and durvalumab, respectively, to platinum-based chemotherapy as first-line treatment for advanced or recurrent EC
• Published efficacy and safety outcomes from the RUBY, NRG-GY018 and DUO-E trials
• Antitumor activity observed with chemotherapy in combination with dostarlimab, pembrolizumab and durvalumab, respectively, in various patient subgroups —based on microsatellite instability (MSI)/mismatch repair (MMR) status, HER2 status, molecular subtype, et cetera — in the RUBY, NRG-GY018 and DUO-E trials
• FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for patients with advanced or recurrent EC regardless of MMR status; optimal incorporation into up-front therapy
• Ongoing Phase III studies, such as DOMENICA and KEYNOTE-C93, evaluating first-line anti-PD-1/PD-L1 inhibitor monotherapy for MSI-high /MMR-deficient advanced or recurrent EC

MODULE 2: Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC

• Rationale for the evaluation of PARP inhibition for advanced EC; possible therapeutic synergy between anti-PD-1/PD-L1 antibodies and PARP inhibitors
• Key efficacy and safety findings from the Phase III RUBY Part 2 and DUO-E trials evaluating first-line chemoimmunotherapy followed by anti-PD-1/PD-L1 antibody/PARP inhibitor maintenance therapy for newly diagnosed advanced or recurrent EC
• Outcomes with PARP inhibitors in various patient subsets of the RUBY Part 2 and DUO-E studies
• Potential patient selection for and role of anti-PD-1/PD-L1 antibody/PARP inhibitor maintenance therapy for advanced EC
• Long-term efficacy and safety findings from the Phase III KEYNOTE-775 trial comparing lenvatinib/pembrolizumab to chemotherapy for patients with advanced EC previously treated with a platinum-based regimen
• Strategies to safely and effectively utilize pembrolizumab/lenvatinib; approaches to dosing and side-effect prevention and management
• Current role of pembrolizumab/lenvatinib in EC management algorithms

MODULE 3: Promising Agents Under Investigation for EC

• Biological rationale for the evaluation of TROP2-directed antibody-drug conjugates (ADCs) for advanced EC
• Preliminary efficacy and safety findings reported with TROP2-directed ADCs for patients with pretreated advanced EC
• Emerging positive findings from the Phase III TroFuse-005 trial of sacituzumab tirumotecan versus chemotherapy for patients with advanced or recurrent EC who have experienced disease progression after platinum-based chemotherapy and an anti-PD-1/PD-L1 antibody 
• Other ongoing Phase III trials evaluating TROP2-directed ADCs
• Mechanism of action of selinexor and biological rationale for its evaluation in EC, particularly for TP53 wild-type disease
• Updated efficacy and safety findings with and ongoing Phase III evaluation of selinexor as maintenance therapy after first-line chemotherapy for patients with TP53 wild-type advanced or recurrent EC
• Other promising agents and strategies, including B7-H4-targeted ADCs, under investigation for advanced EC

Target Audience
This activity is intended for medical and gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Assess the clinical and biological characteristics of the various histologic subtypes and molecular subgroups of endometrial cancer (EC), and consider the implications for prognosis, biomarker evaluation and therapeutic decision-making.
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with microsatellite instability-high/mismatch repair (MMR)-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
• Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
• Review available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic EC to receive this novel approach.
• Recognize the biological rationale for the evaluation of trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugates for patients with EC, and consider available research findings with and potential of these agents.
• Recognize adverse events associated with available and investigational therapies used in the treatment of EC to educate patients and manage complications.
• Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Backes — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, ImmunoGen Inc, Merck, Tubulis; Contracted Research: ImmunoGen Inc, Merck, Natera Inc; Data and Safety Monitoring Boards/Committees: MacroGenics Inc. Dr Slomovitz — Advisory Committees: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, BeOne, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, Incyte Corporation, Karyopharm Therapeutics, Merck, Novocure Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Consulting Agreements: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, Genmab US Inc, GSK, Karyopharm Therapeutics, Seagen Inc; Data and Safety Monitoring Boards/Committees: Genelux.

MODERATOR
Dr Westin — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Faeth Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Ottimo Pharma, Pfizer Inc, pharmaand GmbH, PMV Pharma, Seagen Inc, Verastem Inc, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Verastem Inc, Zentalis Pharmaceuticals.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Eisai Inc, Gilead Sciences Inc, GSK, Karyopharm Therapeutics, and Merck.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room B (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:30 PM on Sunday, May 31st. If you are interested in attending, please visit the registration desk outside Continental Room B (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Faculty

Faculty

Sara A Hurvitz

MD, FACP

Fred Hutchinson Cancer Center, Seattle, Washington

Professor of Medicine, Smith Family Endowed Chair in Women’s Health, Senior Vice President, Clinical Research Division

UW Medicine, Seattle, Washington

Head, Division of Hematology/Oncology, Department of Medicine

Faculty

Erica Mayer

MD, MPH, FASCO

Dana-Farber Cancer Institute, Boston, Massachusetts

Director of Breast Cancer Clinical Research, Breast Oncology Center

Harvard Medical School, Boston, Massachusetts

Associate Professor of Medicine

Faculty

Joyce O’Shaughnessy

MD

Baylor University Medical Center, Dallas, Texas

Celebrating Women Chair in Breast Cancer Research

Texas Oncology, Sarah Cannon Research Institute, Dallas, Texas

Director, Breast Cancer Research Program

Moderator

Sara M Tolaney

MD, MPH

Dana-Farber Cancer Institute, Boston, Massachusetts

Chief, Division of Breast Oncology

Harvard Medical School, Boston, Massachusetts

Associate Professor of Medicine

Faculty

Nicholas Turner

MD, PhD

The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom

Director of Clinical Research, Director, NIHR Biomedical Research Centre, Professor of Molecular Oncology, ICR

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer (mBC)

• Optimal approach to and timing of biomarker assessment for patients with HR-positive mBC; increasing relevance of biomarker evaluation in the up-front setting
• Key findings, including overall survival data, from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib and fulvestrant as first-line therapy for patients with HR-positive, HER2-negative mBC with a PIK3CA mutation whose disease progressed during or within 12 months of adjuvant endocrine therapy
• FDA approval of inavolisib/palbociclib/fulvestrant and clinical role in the treatment of newly diagnosed HR-positive, HER2-negative mBC with a PIK3CA mutation
• Design, eligibility criteria and key endpoints of the Phase III SERENA-6 study evaluating a switch from an aromatase inhibitor (AI) to camizestrant after detection of an emergent ESR1 mutation during first-line therapy for HR-positive, HER2-negative mBC
• Published findings from the SERENA-6 trial; potential role of serial ESR1 testing using circulating tumor DNA (ctDNA) and early therapeutic switching in the care of patients found to harbor mutations
• Emerging negative findings from the Phase III persevERA trial of giredestrant and palbociclib versus letrozole and palbociclib as first-line therapy for patients with HR-positive, HER2-negative mBC 
• Ongoing Phase III trials evaluating PI3K/AKT/mTOR pathway inhibitors (eg, the INAVO123, CAPItello-292 and VIKTORIA-2 studies) and oral SERDs (eg, the SERENA-4 and pionERA studies) as a component of first-line therapy for patients with HR-positive, HER2-negative mBC; estimated completion dates

MODULE 2: Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC

• Structural and mechanistic similarities and differences between fulvestrant and approved and investigational oral SERDs; implications for antitumor activity, tolerability and ease of use
• Published efficacy and safety results from the Phase III EMERALD trial and real-world datasets evaluating elacestrant for pretreated HR-positive, HER2-negative mBC
• Updated efficacy results documented with imlunestrant monotherapy in the Phase III EMBER-3 study evaluating that agent alone or in combination with abemaciclib for patients with HR-positive, HER2-negative mBC pretreated with endocrine therapy with or without a CDK4/6 inhibitor
• FDA approvals of elacestrant and imlunestrant for previously treated HR-positive, HER2-negative, ESR1-mutated mBC; optimal incorporation into management algorithms
• Available findings with other oral SERDs administered as monotherapy for advanced HR-positive, HER2-negative breast cancer

MODULE 3: Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC

• Biological rationale for combining oral SERDs with other systemic therapies for HR-positive mBC
• Updated efficacy and safety outcomes documented in the imlunestrant/abemaciclib arm of the EMBER-3 trial among patients with and without ESR1 mutations
• Indications, if any, for the nonresearch use of imlunestrant in combination with abemaciclib for endocrine therapy-pretreated, HR-positive, HER2-positive mBC
• Key data from the Phase III evERA study of giredestrant in combination with everolimus versus standard endocrine therapy in combination with everolimus for pretreated HR-positive, HER2-negative mBC
• Potential clinical role of giredestrant/everolimus for previously treated HR-positive, HER2-positive mBC
• Early-phase data with and ongoing evaluation of other oral SERD-containing combination strategies for progressive HR-positive, HER2-negative mBC

MODULE 4: Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC

• Key efficacy and safety data from the Phase III CAPItello-291 study evaluating capivasertib/fulvestrant for HR-positive, HER2-negative mBC progressing on endocrine therapy with or without a CDK4/6 inhibitor
• FDA approval of capivasertib for patients with previously treated HR-positive, HER2-positive mBC and PIK3CA/AKT1/PTEN alterations; current therapeutic role with regard to other evidence-based options
• Mechanistic similarities and differences between gedatolisib and currently approved therapies targeting the PI3K/AKT/mTOR pathway in HR-positive mBC; implications for antitumor activity
• Design, eligibility criteria and primary and secondary endpoints of the Phase III VIKTORIA-1 trial evaluating gedatolisib in combination with fulvestrant with or without palbociclib for patients with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior CDK4/6 inhibitor therapy and an AI
• Recently published efficacy and safety findings from the PIK3CA wild-type cohort of VIKTORIA-1; emerging positive findings from and anticipated readout of the PIK3CA-mutated cohort
• Potential role of gedatolisib-containing combination therapy for pretreated HR-positive, HER2-negative mBC that is PIK3CA wild type and PIK3CA mutated

MODULE 5: Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer

• Rationale for the investigation of oral SERDs as adjuvant therapy for patients with HR-positive, HER2-negative localized breast cancer
• Design, eligibility criteria and primary and second endpoints of the Phase III lidERA Breast Cancer study evaluating adjuvant giredestrant versus physician’s choice of adjuvant endocrine monotherapy for patients with HR-positive, HER2-negative localized breast cancer
• Improvement in invasive disease-free survival and other key efficacy outcomes documented with adjuvant giredestrant in the lidERA Breast Cancer trial
• Tolerability profile of giredestrant versus standard adjuvant endocrine therapy in the lidERA Breast Cancertrial
• Potential clinical role of adjuvant giredestrant for patients with HR-positive, HER2-negative localized breast cancer
• Early data with and ongoing Phase III trials (eg, the ELEGANT, TREAT ctDNA, EMBER-4, CAMBRIA-1 and CAMBRIA-2 studies) of other oral SERDs in the adjuvant setting

Target Audience
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, general and breast surgeons and other healthcare providers involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the incidence and clinical implications of ESR1 mutations in endocrine-resistant metastatic breast cancer (mBC), and determine optimal strategies to effectively identify patients harboring these abnormalities.
• Understand the biological rationale for, mechanism of action of and pharmacologic similarities and differences among available and investigational oral selective estrogen receptor degraders (SERDs).
• Interrogate published research documenting the efficacy of oral SERD monotherapy for hormone receptor (HR)-positive, HER2-negative, ESR1-mutated mBC progressing on standard endocrine therapy in combination with a CDK4/6 inhibitor in order to optimally integrate these agents into the care of appropriately selected patients.
• Review available research data evaluating serial ESR1 testing using circulating tumor DNA to inform early therapeutic switching for patients with HR-positive mBC receiving CDK4/6 inhibitor-based first-line therapy, and consider the potential role of this novel strategy. 
• Evaluate available clinical trial data with oral SERDs in combination with other systemic therapies (eg, CDK4/6 inhibitors, mTOR inhibitors), and consider the potential role of these regimens.
• Recognize the frequency of PIK3CA/AKT/PTEN alterations in patients with hormone receptor (HR)-positive mBC, and employ evidence-based approaches to target these aberrations for appropriate candidates with newly diagnosed and relapsed/refractory disease.
• Understand the biological rationale for the development of agents targeting multiple components of the PI3K/AKT/mTOR pathway, and recognize available data employing this strategy for patients with HR-positive, PIK3CA wild-type and PIK3CA-mutant mBC.
• Appreciate side effects associated with available and investigational oral SERDs and agents targeting the PI3K/AKT/mTOR pathway, and use this information to develop supportive care plans for patients receiving these treatments.
• Assess ongoing clinical research studies evaluating novel applications of oral SERDs and PI3K/AKT/mTOR inhibitor-based approaches, and counsel patients regarding the potential benefits of trial participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

Dr Hurvitz — Advisory Committees: Akari Therapeutics, BeOne, Boundless Bio, BriaCell, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Lilly, Luminate, Mersana Therapeutics Inc, Novartis, Prelude Therapeutics, Roche Laboratories Inc; Consulting Agreements: ALX Oncology, Bayer HealthCare Pharmaceuticals, BeOne, Blueprint Medicines, Ellipses Pharma, EMBioSys, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Myricx Bio; Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Menarini Group, Novartis, Stemline Therapeutics Inc; Data and Safety Monitoring Boards/Committees: Atossa Therapeutics (paid to institution), Roche Laboratories Inc (paid to UW); Nonrelevant Financial Relationships: Alliance for Clinical Trials in Oncology Foundation, InClin, Quantum Leap Healthcare Collaborative, ROMTech (stocks for orthopedic device for postop pts; not cancer related). Dr Mayer — Consulting Agreements: Aktis Oncology, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Lilly, Novartis. Dr O’Shaughnessy — Advisory Committees and Consulting Agreements: Aadi Bioscience, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Ellipses Pharma, Exact Sciences Corporation, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, HiberCell, Jazz Pharmaceuticals Inc, Johnson & Johnson, Lilly, Menarini Group, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, RayzeBio, Roche Laboratories Inc, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Summit Therapeutics, Tempus, TerSera Therapeutics LLC. Dr Turner —Consultant/Advisory: AstraZeneca Pharmaceuticals LP, Exact Sciences Corporation, Genentech, a member of the Roche Group, GSK, Guardant Health, Inivata, Lilly, Novartis, Pfizer Inc, Repare Therapeutics; Research Funding: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Guardant Health, Inivata, Invitae, Labcorp, MSD, Natera Inc, Personalis, Pfizer Inc.

MODERATOR
Dr Tolaney — Consulting Agreements: Aadi Bioscience, Ambrx, Artios Pharma Limited, Arvinas, AstraZeneca Pharmaceuticals LP, Aktis Oncology, Avenzo Therapeutics, Bayer HealthCare Pharmaceuticals, BeOne, Bicycle Therapeutics, BioNTech SE, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boundless Bio, Bristol Myers Squibb, Celcuity, Circle Pharma, Cullinan Therapeutics, Daiichi Sankyo Inc, Denali Therapeutics, eFFECTOR Therapeutics Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Hengrui Therapeutics Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Launch Therapeutics, Lilly, Menarini Group, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Olema Oncology, Pfizer Inc, Reveal Genomics, Samsung Bioepis, Seagen Inc, Stemline Therapeutics Inc, Sumitovant Biopharma, Summit Therapeutics, SystImmune Inc, Tango Therapeutics, Tempus, Zuellig Pharma; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Lilly, Menarini Group, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer Inc, Seagen Inc, Stemline Therapeutics Inc; Travel: Arvinas, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Lilly, Pfizer Inc, Roche Laboratories Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celcuity, Genentech, a member of the Roche Group, Lilly, and Stemline Therapeutics Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room A (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:30 PM on Sunday, May 31st. If you are interested in attending, please visit the registration desk outside Continental Room A (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Faculty

Faculty

Anne Chiang

MD, PhD

Yale University School of Medicine, New Haven, Connecticut

Associate Professor

Yale Cancer Center, New Haven, Connecticut

Associate Cancer Center Director, Clinical Initiatives

Faculty

Apar Kishor Ganti

MD, MS

University of Nebraska Medical Center, Omaha, Nebraska

Doctor and Mrs D Leon UNMC Research Fund Chair in Internal Medicine, Professor of Medicine, Division of Oncology-Hematology, Professor (Courtesy) of Biochemistry and Molecular Biology

VA Nebraska Western Iowa Health Care System, Omaha, Nebraska

Staff Physician

Faculty

Luis Paz-Ares

MD, PhD

Hospital Universitario 12 de Octubre, Madrid, Spain

Chair of the Medical Oncology Department

Universidad Complutense, Madrid, Spain

Professor of Medicine

National Oncology Research Center, Madrid, Spain

Head of the Lung Cancer Unit

Moderator

Misty Dawn Shields

MD, PhD

Indiana University School of Medicine, Indianapolis, Indiana

Assistant Professor of Clinical Medicine

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

Adjunct Assistant Professor of Medical and Molecular Genetics, Associate Member, Experimental and Developmental Therapeutics, Department of Medicine, Division of Hematology/Oncology, Thoracic Oncology

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

• Long-term outcomes with durvalumab and atezolizumab, respectively, in combination with platinum-based chemotherapy as first-line treatment for patients with ES-SCLC
• Appropriate integration of first-line atezolizumab/carboplatin/etoposide and durvalumab/platinum/etoposide into current ES-SCLC management
• Rationale for the design of the Phase III IMforte trial evaluating lurbinectedin with atezolizumab versus atezolizumab alone as maintenance therapy after induction atezolizumab/carboplatin/etoposide for patients with ES-SCLC
• Published efficacy and safety findings with the addition of lurbinectedin to maintenance atezolizumab in the IMforte trial
• Recent FDA approval of lurbinectedin in combination with atezolizumab as maintenance treatment for ES-SCLC after first-line induction therapy with atezolizumab/carboplatin/etoposide; appropriate selection of patients for this strategy
• Other ongoing research studies evaluating novel first-line and maintenance strategies

MODULE 2: Management of Relapsed/Refractory (R/R) SCLC

• Factors in the selection and sequencing of therapy for R/R SCLC
• Available research findings with and current clinical role of lurbinectedin for patients with SCLC that has progressed after platinum-based therapy
• Scientific rationale for targeting delta-like ligand 3 (DLL3) in SCLC; mechanism of action of the DLL3 x CD3 bispecific T-cell engagers tarlatamab and obrixtamig
• Key efficacy and safety findings from the Phase III DeLLphi-304 study of tarlatamab for previously treated SCLC; FDA approval and current clinical role
• Safety profile of tarlatamab, including rates and severity of cytokine release syndrome and neurotoxicity/immune effector cell-associated neurotoxicity syndrome; appropriate monitoring, mitigation and management of adverse events
• Early data with and ongoing evaluation of obrixtamig for patients with R/R SCLC

MODULE 3: Ongoing Investigation and Potential Role of Antibody-Drug Conjugates for SCLC

• Rationale for targeting B7-H3 in SCLC; mechanism of action of the B7-H3-directed antibody-drug conjugate ifinatamab deruxtecan (I-DXd)
• Clinical outcomes observed with I-DXd among patients with recurrent ES-SCLC in the Phase II Ideate-Lung 01 trial
• Ongoing studies, such as IDeate-Lung02 and IDeate-Lung03, evaluating I-DXd alone and in combination with other systemic therapies for ES-SCLC; potential clinical role
• Published efficacy and safety data with sacituzumab govitecan as second-line therapy for ES-SCLC
• FDA breakthrough therapy designation for sacituzumab govitecan for patients with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy; potential clinical role in this setting
• Design, eligibility criteria and primary and secondary endpoints of the Phase III EVOKE-SCLC-04 study evaluating sacituzumab govitecan versus chemotherapy for previously treated ES-SCLC; estimated completion date
• Other novel antibody-drug conjugates under investigation for ES-SCLC

MODULE 4: Management of Limited-Stage SCLC (LS-SCLC)

• Long-term outcomes achieved with historical treatment approaches for LS-SCLC; rationale for the investigation of immune checkpoint inhibition
• Major efficacy findings from the Phase III ADRIATIC trial assessing durvalumab as consolidation treatment for patients with LS-SCLC after completion of chemoradiation therapy (CRT)
• Tolerability profile documented with consolidation durvalumab in the ADRIATIC trial
• FDA approval and current clinical role of durvalumab consolidation for LS-SCLC
• Ongoing Phase IIIb ALBORAN study evaluating durvalumab after CRT in a real-world population of patients with LS-SCLC
• Design, eligibility criteria and primary and secondary endpoints of the Phase III DeLLphi-306 study evaluating tarlatamab after CRT for LS-SCLC; estimated completion date

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to 

• Appraise available findings from clinical studies investigating anti-PD-1/PD-L1 antibody consolidation therapy for patients with limited-stage small cell lung cancer (SCLC) who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and determine the clinical role of this approach.
• Review long-term data supporting the use of anti-PD-1/PD-L1 antibodies in combination with platinum-based chemotherapy as first-line therapy for patients with extensive-stage SCLC, and consider how these regimens can be appropriately and safely integrated into clinical practice.
• Appreciate the biological rationale for the evaluation of maintenance treatment after chemoimmunotherapy induction, and assess available research findings with and the current role of this approach.
• Evaluate available clinical trial findings with FDA-approved agents for patients with SCLC who experience disease progression on or after platinum-containing first-line therapy, and determine how to optimally integrate these therapies into current treatment algorithms.
• Interrogate published clinical trial data with DLL3-directed T-cell engager therapy for SCLC, and identify patients with relapsed/refractory (R/R) disease appropriate for this novel approach.
• Appreciate the incidence of B7-H3 overexpression in patients with SCLC, and develop an understanding of the rationale for, available data with and ongoing studies of B7-H3-directed antibody-drug conjugates for R/R disease.
• Reflect on the biological rationale for the evaluation of TROP2-directed antibody-drug conjugates for SCLC, and consider available research findings and ongoing studies with these agents.
• Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for the management of patients with SCLC, and counsel patients regarding the potential benefits of trial participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Chiang — Advisory Committees: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Zai Lab; Consulting Agreements: AbbVie Inc, Merck; Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Zai Lab; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP; Honoraria for Lectures: Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc. Dr Ganti — Advisory Committees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Catalyst Pharmaceuticals Inc, Fosun Pharma, Merck, Pfizer Inc, Zai Lab; Consulting Agreements: Cardinal Health, Jazz Pharmaceuticals Inc; Contracted Research: Imugene, Iovance Biotherapeutics, Merck, Mirati Therapeutics Inc, Poseida Therapeutics. Dr Paz-Ares — Advisory Committees: Abbott, AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, MSD, Pfizer Inc; Board Memberships: Altum Sequencing, STAb Therapeutics.

CONTRIBUTING CLINICAL INVESTIGATORS
Charu Aggarwal, MD — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Lilly, Merck. Ticiana Leal, MD — Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Boehringer Ingelheim Pharmaceuticals Inc, Catalyst Pharmaceuticals Inc, Gilead Sciences Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Novartis, Novocure Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Advaxis Inc, Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc, Pfizer Inc, Synthekine; Data and Safety Monitoring Board/Committee: OncoC4; Travel Support: Regeneron Pharmaceuticals Inc, Sanofi.

MODERATOR
Dr Shields — Steering Committees: AstraZeneca Pharmaceuticals LP.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, and Merck.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room A (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:30 PM on Saturday, May 30th. If you are interested in attending, please visit the registration desk outside Continental Room A (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Faculty

Faculty

Wassim Abida

MD, PhD

Memorial Sloan Kettering Cancer Center, New York, New York

Director of Translational Research in Prostate Cancer, Associate Member, Genitourinary Oncology Service

Weill Cornell Medical College, New York, New York

Associate Professor of Medicine

Faculty

Rahul Aggarwal

MD

University of California, San Francisco, San Francisco, California

Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research, Program Leader, Genitourinary Medical Oncology, Division of Hematology/Oncology

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Associate Director for Clinical Research

Faculty

Emmanuel S Antonarakis

MD

University of Minnesota, Minneapolis, Minnesota

Clark Endowed Professor of Medicine, Division of Hematology, Oncology and Transplantation

Moderator

Rana R McKay

MD, FASCO

Moores Cancer Center, University of California San Diego, San Diego, California

Professor of Medicine, Urology, and Radiation Medicine and Applied Sciences, Associate Director, Clinical Research, Co-Lead, Genitourinary Program

Faculty

Karim Fizazi

MD, PhD

Centre Oscar Lambret, Lille, France

Director

University of Paris Saclay, Lille, France

GETUG President, ESMO Public Policy Director

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (nmHSPC)

• Rationale for the evaluation of treatment intensification with androgen receptor (AR) pathway inhibitors for patients with nmHSPC
• Design, eligibility criteria and primary and secondary endpoints of the Phase III PROTEUS trial of perioperative apalutamide and androgen deprivation therapy (ADT) for high-risk localized or locally advanced prostate cancer; anticipated read-out 
• Major efficacy and safety data, including overall survival outcomes, from the Phase III EMBARK trial evaluating enzalutamide and leuprolide versus enzalutamide or leuprolide alone for patients with nmHSPC and high-risk biochemical recurrence after definitive therapy
• FDA approval and optimal application of enzalutamide with and without ADT in clinical practice
• Published data with ADT intensification with apalutamide with or without abiraterone for patients with high-risk biochemically recurrent nmHSPC
• Other ongoing Phase III studies evaluating AR pathway inhibitors for patients with nmHSPC 

MODULE 2: Current Hormonal Treatment for Metastatic HSPC (mHSPC)

• Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for patients with mHSPC
• Published data from the Phase III ARANOTE study supporting the recent FDA approval of darolutamide/ADT for mHSPC
• Clinical factors guiding the selection of a specific AR pathway inhibitor for patients with mHSPC; available datasets exploring the relative benefits of various approved agents
• Published efficacy and safety data from the Phase III ARASENS trial evaluating darolutamide in combination with docetaxel and ADT for mHSPC
• Optimal selection of candidates with mHSPC for triplet therapy with darolutamide/docetaxel/ADT

MODULE 3: Current and Future Role of Regimens Combining PARP Inhibitors and AR Pathway Inhibitors in Treatment for Metastatic Prostate Cancer

• Incidence and clinical implications of BRCA1/2 and other homologous recombination repair (HRR) abnormalities in patients with metastatic prostate cancer; recommended timing and optimal method for genetic testing
• Biological rationale for combining PARP inhibitors with secondary hormonal agents in the treatment of metastatic prostate cancer
• Long-term efficacy and safety findings from the Phase III PROpel, MAGNITUDE and TALAPRO-2 trials combining olaparib and abiraterone, niraparib and abiraterone and talazoparib and enzalutamide, respectively, in the first-line setting for patients with metastatic castration-resistant prostate cancer (mCRPC)
• FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide for mCRPC; appropriate selection of a PARP inhibitor/secondary hormonal therapy combination for individual patients
• Published data from the Phase III AMPLITUDE trial evaluating the addition of niraparib to abiraterone/prednisone for patients with mHSPC harboring alterations in HRR genes; recent FDA approval of this strategy for patients with BRCA2 mutations
• Emerging positive findings from the Phase III TALAPRO-3 study of talazoparib in combination with enzalutamide for patients with HRR-mutated mHSPC 
• Mechanistic similarities and differences between saruparib and other PARP inhibitors; ongoing Phase III efforts evaluating saruparib

MODULE 4: Emerging Role of AKT Inhibition in Therapy for Patients with mHSPC

• Biological justification for targeting the PI3K/AKT/mTOR pathway with capivasertib in prostate cancer; rationale for benefit for patients with PTEN-deficient disease
• Frequency of PTEN deficiency in prostate cancer; indications for and optimal timing of and approach to PTEN assessment
• Design, eligibility criteria and primary and secondary endpoints of the Phase III CAPItello-281 trial assessing capivasertib with abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency
• Recently presented positive results from the CAPItello-281 trial with the addition of capivasertib to abiraterone/ADT for PTEN-deficient mHSPC
• Spectrum of toxicities associated with capivasertib; recommended monitoring and management strategies
• Potential integration of capivasertib/abiraterone/ADT into mHSPC treatment algorithms; optimal use with regard to other currently available regimens

MODULE 5: Current and Future Use of Radiopharmaceuticals for Metastatic Prostate Cancer

• Long-term data with and current role of radium-223 monotherapy in mCRPC treatment algorithms
• Key efficacy and safety findings from the Phase III PEACE III trial of radium-223 and enzalutamide versus enzalutamide alone as first-line therapy for mCRPC with bone metastases; implications for clinical management
• Published Phase III datasets with lutetium Lu 177 vipivotide tetraxetan for patients with taxane-naïve and taxane-pretreated, PSMA-positive mCRPC; appropriate sequencing with regard to other available therapies
• Recently presented results from the Phase III PSMAddition study evaluating the addition of lutetium Lu 177 vipivotide tetraxetan to hormonal therapy for patients with PSMA-positive mHSPC; implications for clinical practice
• Early findings with and ongoing evaluation of other PSMA-targeted radiopharmaceuticals for metastatic prostate cancer

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to 

• Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for patients with consideration of the risks and potential benefits of new and established forms of hormonal therapy.
• Appraise published research findings on optimal therapeutic approaches for patients with biochemical recurrence after local therapy for prostate cancer, and counsel appropriate candidates regarding the potential benefits of FDA-approved systemic treatment options.
• Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options for patients.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into clinical management algorithms.
• Assess the available research database supporting the use of PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
• Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway in prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
• Review available Phase III data documenting the efficacy of various forms of radioligand therapy for patients with metastatic prostate cancer, and consider the current and future clinical role of these strategies.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Abida — Advisory Committees: AstraZeneca Pharmaceuticals LP, K36 Therapeutics, Nuvation Bio Inc, ORIC Pharmaceuticals; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boundless Bio, Duality Biologics, Endeavor BioMedicines, Tolmar; Contracted Research: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, K36 Therapeutics, Merus, MOMA Therapeutics, Nuvation Bio Inc, ORIC Pharmaceuticals, TransThera. Dr Aggarwal — Advisory Committees: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Merck, Pfizer Inc; Consulting Agreements: Boxer Capital Management, EcoR1 Capital LLC, Genentech, a member of the Roche Group; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Johnson & Johnson, Merck, Novartis, Zenith Epigenetics; Nonrelevant Financial Relationships: Prostate Cancer Clinical Trials Consortium. Dr Antonarakis — Advisory Committees: Abeona Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Curium, Merck, Pfizer Inc, Sanofi, Tango Therapeutics, Tempus, Vir Biotechnology Inc; Consulting Agreements: Acerand Therapeutics, Blue Earth Diagnostics, Boundless Bio, Clarivate, Clearview Healthcare Partners, Curium, DAVA Oncology, EcoR1 Capital LLC, Global Life Sciences Alliance, Health Monitor Network, Johnson & Johnson, Lilly, Lumanity, Propella Therapeutics Inc, Slingshot Insights, Third Bridge, Z-Alpha; Contracted Research: Actinium Pharmaceuticals Inc, MacroGenics Inc, Merck, MorphoSys, Novartis, Orion Corporation, pharmaand GmbH, Seagen Inc; Patents: QIAGEN; Nonrelevant Financial Relationships: Binaytara Foundation, Conexiant, eCancer, Fred Hutch Cancer Center, MJH Life Sciences, Targeted Oncology, The Medical Educator Consortium. Prof Fizazi — Honoraria, Former Institution: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck, MSD, Novartis, Pfizer Inc.

MODERATOR
Dr McKay — Advisory Committees and Consulting Agreements: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Neomorph, Nimbus Therapeutics, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: Artera, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Incyte Corporation, Natera Inc, Oncternal Therapeutics.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Merck, and Novartis.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room B (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:30 PM on Saturday, May 30th. If you are interested in attending, please visit the registration desk outside Continental Room B (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Faculty

Faculty

Ramez N Eskander

MD

UC San Diego Health, Rebecca and John Moores NCI-Designated Comprehensive Cancer Center, San Diego, California

Julie St John Endowed Chair in Gynecologic Oncology, Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, Clinical Trials Office Medical Director, Fellowship Director – Gynecologic Oncology

Faculty

Ursula Matulonis

MD

Dana-Farber Cancer Institute, Boston, Massachusetts

Chief, Division of Gynecologic Oncology, Brock-Wilson Family Chair

Harvard Medical School, Boston, Massachusetts

Professor of Medicine

Faculty

Alexander B Olawaiye

MD

University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Professor, Department of Obstetrics, Gynecology and Reproductive Sciences

Moderator

Kathleen N Moore

MD, MS

Fred and Pamela Buffett Cancer Center at the University of Nebraska, Omaha, Nebraska

Deputy Director and Director, Phase 1 Clinical Trials

Faculty

David M O'Malley

MD

The Ohio State University and The James Comprehensive Cancer Center, Columbus, Ohio

Director and Professor, Division of Gynecologic Oncology in Obstetrics and Gynecology, John G Boutselis Chair in Gynecologic Oncology

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC)

• Optimal approaches to biomarker testing for patients with newly diagnosed advanced OC; significance of somatic and germline BRCA mutations and homologous recombination deficiency status in treatment decision-making
• Long-term findings, including overall survival (OS) outcomes, with olaparib, olaparib/bevacizumab and niraparib maintenance therapy for patients with newly diagnosed OC
• Clinical, biological and practical factors in the selection of up-front maintenance olaparib, olaparib/bevacizumab or niraparib
• Ongoing Phase III studies, such as MONO-OLA1 and NRG-GY036, further exploring up-front PARP inhibitor maintenance therapy
• Current clinical utility, if any, of PARP inhibitors for patients with relapsed/refractory OC, including those who have experienced disease progression after PARP inhibitor therapy

MODULE 2: Strategies Targeting Folate Receptor Alpha (FRα) in Advanced OC

• Incidence and clinical relevance of FRα expression in OC; optimal approaches to and timing of FRα testing
• Long-term data, including OS findings, with mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant OC from the Phase III MIRASOL trial; optimal integration into current management algorithms
• Key findings from the Phase II PICCOLO and MIROVA trials of mirvetuximab soravtansine for FRα-positive, platinum-sensitive OC; potential clinical role
• Design, eligibility criteria and primary and secondary endpoints of the Phase III GLORIOSA trial evaluating mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive OC who have not experienced disease progression after second-line platinum-based chemotherapy and bevacizumab
• Mechanistic similarities and differences between investigational FRα-targeted antibody-drug conjugates, such as rinatabart sesutecan, torvutatug samrotecan and sofetabart mipitecan, and mirvetuximab soravtansine
• Early data with and ongoing evaluation of investigational FRα-targeted antibody-drug conjugates for FRα-expressing, platinum-resistant OC

MODULE 3: Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC

• Frequency of HER2 expression in advanced OC; outcomes observed among patients with OC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan (T-DXd) for pretreated HER2-expressing solid tumors
• Recent tumor-agnostic FDA approval of T-DXd and implications for OC management
• Ongoing Phase III DESTINY-Ovarian01 trial seeking to further define the role of T-DXd in therapy for advanced OC
• Rationale for targeting CDH6 in advanced OC; mechanism of antitumor activity of raludotatug deruxtecan (R-DXd)
• Available research findings, including those from the Phase II dose-optimization part of the ongoing Phase II/III REJOICE-Ovarian01 study, with R-DXd for patients with platinum-resistant advanced OC
• FDA breakthrough therapy designation of R-DXd for patients with platinum-resistant epithelial OC expressing CDH6 who have received prior treatment with bevacizumab; potential clinical role
• Early efficacy and safety outcomes with and ongoing evaluation of TROP2-directed antibody-drug conjugates for patients with advanced OC
• Other promising targets for antibody-drug conjugates, such as B7-H4, under investigation for patients with advanced OC

MODULE 4: Other Novel Agents and Strategies for Advanced OC

• Mechanism of antitumor activity of the selective glucocorticoid receptor modulator relacorilant and rationale for its evaluation for advanced OC
• Published efficacy and safety findings from the Phase III ROSELLA study of relacorilant and nab paclitaxel versus nab paclitaxel alone for patients with platinum-resistant advanced OC
• Tolerability profile of relacorilant/nab paclitaxel in the ROSELLA trial; relative contributions of each agent with regard to toxicities
• Recent FDA approval of relacorilant/nab paclitaxel for platinum-resistant advanced OC; integration into current clinical algorithms
• Available data, including OS outcomes, from the Phase III KEYNOTE-B96 study evaluating the addition of pembrolizumab to chemotherapy with or without bevacizumab for patients with platinum-resistant recurrent OC
• Recent FDA approval of pembrolizumab in combination with chemotherapy with or without bevacizumab and current clinical role in therapy for platinum-resistant recurrent OC

MODULE 5: Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC

• Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors for OC
• Optimal monitoring, mitigation and management approaches for common PARP inhibitor-related toxicities
• Reported risk of long-term, serious side effects, such as myelodysplastic syndromes or acute myeloid leukemia, with PARP inhibitor therapy
• Pathogenesis and incidence of ocular adverse reactions associated with mirvetuximab soravtansine; recommended approaches to prevention, monitoring and management
• Spectrum, frequency, severity and management of other side effects, such as peripheral neuropathy, gastrointestinal (GI) toxicities, fatigue and pneumonitis, in patients receiving mirvetuximab soravtansine
• Spectrum and incidence of common (eg, GI toxicities, myelosuppression) and more serious (eg, interstitial lung disease, cardiac toxicities) treatment-emergent adverse events observed with T-DXd
• Recommended strategies to monitor for, mitigate and manage T-DXd-associated toxicities

Target Audience
This activity is intended for medical and gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian cancer (OC).

Learning Objectives
Upon completion of this activity, participants should be able to 

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced OC, and appropriately counsel patients regarding personalized treatment recommendations.
• Appraise biological and patient- and treatment-related factors in order to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
• Recognize the rationale for targeting folate receptor alpha (FRα) in OC, and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates (ADCs).
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the current role of this novel therapeutic strategy.
• Understand the biological justification for the evaluation of selective glucocorticoid receptor modulators in combination with chemotherapy for patients with platinum-resistant OC, and recall available Phase III findings with this novel approach.
• Assess the incidence of cadherin-6 expression in OC, and understand the structural components of, mechanism of action of and available data with novel ADCs directed at this target.
• Review published clinical research findings documenting the efficacy of HER2-targeted agents and regimens in patients with HER2-overexpressing OC and other gynecologic cancers, and consider the role of ADCs and other approaches.
• Describe the scientific justification for, published research data with and current research studies of other novel agents and strategies in OC, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Eskander — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Foundation Medicine, Gilead Sciences Inc, GSK, ImmunoGen Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MSD, Myriad Genetic Laboratories Inc, Natera Inc, Novocure Inc, Pfizer Inc, pharmaand GmbH, PMV Pharma, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Data and Safety Monitoring Boards/Committees: Xencor. Dr Matulonis — Advisory Committees: AbbVie Inc, Ascendis Pharma, Corcept Therapeutics Inc, Day One Biopharmaceuticals, GSK, Kaida BioPharma, Merck, NextCure, Whitehawk Therapeutics; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, MacroGenics Inc, Mural Oncology Inc, Symphogen A/S. Dr Olawaiye — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, GSK, Lilly, Merck; Consulting Agreements: Corcept Therapeutics Inc; Speakers Bureaus: Foundation Medicine. Dr O’Malley — Consulting Agreements — Personal Fees (Consult and/or Advisory Boards): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, Genmab US Inc, GSK, Lilly, Merck, MSD, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds for Research): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, pharmaand GmbH, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Pharma America, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Data and Safety Monitoring Boards/Committees: Frantz Viral Therapeutics. Additional faculty to be announced.

MODERATOR — Dr Moore — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, GSK, Mersana Therapeutics Inc; Consulting Agreements: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, GSK, ImmunoGen Inc, Janssen Biotech Inc, Merck, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Whitehawk Therapeutics, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Accent Therapeutics, Advaxis Inc, Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, Immunocore, Iovance Biotherapeutics, Regeneron Pharmaceuticals Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics; Nonrelevant Financial Relationships: ASCO, GOG Partners, NRG Oncology.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:30 PM on Saturday, May 30th. If you are interested in attending, please visit the registration desk outside Continental Room C (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Faculty

Faculty

John N Allan

MD

Weill Cornell Medicine, New York, New York

Associate Professor of Clinical Medicine

Faculty

Bita Fakhri

MD, MPH

Stanford University School of Medicine, Stanford, California

Associate Professor of Medicine (Hematology)

Faculty

Shuo Ma

MD, PhD

Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois

Professor of Medicine, Division of Hematology-Oncology, Department of Medicine

Moderator

Jeremy S Abramson

MD, MMSc

Massachusetts General Hospital, Boston, Massachusetts

Director, Center for Lymphoma

Harvard Medical School, Boston, Massachusetts

Professor of Medicine

Faculty

Mazyar Shadman

MD, MPH

Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington

Professor, Innovators Network Endowed Chair, Deputy Chief Medical Officer, Medical Director, Cellular Immunotherapy, Professor, Clinical Research Division

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:30 PM — Educational Meeting

MODULE 1: Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

• Clinical, biological and practical factors in the selection of front-line therapy for patients with CLL requiring treatment
• Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for treatment-naïve and relapsed/refractory (R/R) CLL; application in current up-front decision-making
• Pharmacological similarities and differences between covalent and noncovalent BTK inhibitors
• Key findings from the Phase III BRUIN CLL-314 study of pirtobrutinib versus ibrutinib for patients with treatment-naïve or previously treated, BTK inhibitor-naïve CLL
• Published data with pirtobrutinib versus bendamustine/rituximab for patients with treatment-naïve CLL without del(17p) in the Phase III BRUIN CLL-313 trial
• Potential clinical role of pirtobrutinib in therapy for newly diagnosed CLL

MODULE 2: Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL

• Long-term data with up-front venetoclax/obinutuzumab for CLL
• Mechanistic rationale for combining BTK inhibitors and venetoclax with and without anti-CD20 antibodies for CLL
• Published findings from the Phase III AMPLIFY trial of fixed-duration acalabrutinib in combination with venetoclax with or without obinutuzumab for previously untreated CLL
• Recent FDA approval of fixed-duration acalabrutinib and venetoclax for patients with treatment-naïve CLL; integration into current clinical algorithms
• Early data with zanubrutinib in combination with Bcl-2 inhibitors, such as venetoclax or sonrotoclax, with or without an anti-CD20 antibody, for treatment-naïve CLL
• Efficacy and safety findings from and clinical implications of the Phase III CLL17 trial evaluating fixed-duration versus continuous targeted treatment for previously untreated CLL

MODULE 3: Optimal Management of Adverse Events (AEs) with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations

• Relevant patient comorbidities, such as hypertension, preexisting cardiac arrhythmias, chronic kidney disease and chronic migraines, and concomitant medications that might influence the choice of therapy for CLL
• Spectrum, frequency and severity of cardiovascular AEs with covalent and noncovalent BTK inhibitors; optimal monitoring and management protocols
• Incidence and management of noncardiovascular AEs associated with covalent and noncovalent BTK inhibitors
• Frequency of tumor lysis syndrome and other common AEs reported with venetoclax for CLL, such as cytopenias, infections and gastrointestinal disorders; monitoring, prophylaxis and management protocols
• Incidence, severity and management of clinically relevant toxicities encountered when combining BTK and Bcl-2 inhibitors with or without anti-CD20 antibodies

MODULE 4: Selection and Sequencing of Therapy for R/R CLL

• Clinical and biological factors guiding decision-making for patients with R/R CLL; impact of the evolving up-front CLL treatment paradigm on the management of R/R disease
• Long-term follow-up from Phase III trials evaluating covalent BTK inhibitors and Bcl-2 inhibitors for patients with R/R CLL; current role of rechallenge with an agent or class of agents received in a prior line of therapy
• Published findings from key trials, such as BRUIN and BRUIN CLL-321, supporting the use of pirtobrutinib for patients with R/R CLL
• Emerging positive findings from the Phase III BRUIN CLL-322 trial of pirtobrutinib in combination with venetoclax and rituximab versus venetoclax and rituximab for patients with R/R CLL
• Available and emerging efficacy and safety data with and ongoing evaluation of other noncovalent BTK inhibitors, such as nemtabrutinib and rocbrutinib, for R/R and treatment-naïve CLL

MODULE 5: Other Novel Strategies for CLL

• Biological rationale for the evaluation of CAR T-cell therapy in CLL
• Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for R/R CLL from the Phase I/II TRANSCEND CLL 004 trial
• FDA approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; current clinical role and optimal patient selection
• Early antitumor activity and safety data with bispecific antibodies for R/R CLL and CLL with Richter’s syndrome
• Rationale for the design of the ongoing Phase III SOUNDTRACK-C1 study of the CD19 x CD3 bispecific T-cell engager surovatamig as consolidation therapy for patients with IGHV-unmutated CLL
• Preliminary data with and ongoing Phase III trials of other promising novel agents and strategies, such as sonrotoclax and BTK degraders, for patients with CLL  

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to 

• Individualize the selection of systemic therapy for patients with newly diagnosed CLL, considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available and emerging Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
• Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for newly diagnosed and relapsed/refractory CLL, and identify patients appropriate for treatment with these agents.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented and emerging data with and the current and potential role of this strategy for patients with newly diagnosed and relapsed/refractory CLL.
• Evaluate the biological rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy for CLL, and identify patients for whom treatment with this novel therapeutic strategy would be appropriate.
• Recall available data with novel agents and combination strategies currently under investigation for CLL, and as applicable, discuss clinical trial participation with eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Allan — Advisory Committees: NeoGenomics; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company; Contracted Research: Adaptive Biotechnologies Corporation, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Merck; Speakers Bureaus: AbbVie Inc, BeOne. Dr Fakhri — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, BeOne, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company. Dr Ma — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly; Consulting Agreements: AbbVie Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Carna Biosciences, Juno Therapeutics, a Celgene Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, BeOne, Lilly. Dr Shadman — Advisory Committees and Consulting Agreements: AbbVie Inc, ADC Therapeutics, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, MorphoSys, Nurix Therapeutics Inc, Pfizer Inc, Pierre Fabre; Contracted Research: AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Merck, MorphoSys, Nurix Therapeutics Inc, Sana Biotechnology; Stock OPTIONS — Private Companies: Koi Biotherapeutics Inc; Nonrelevant Financial Relationships: Bristol Myers Squibb (spouse employment).

MODERATOR
Dr Abramson — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Miltenyi Biotec, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Lilly.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room B (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:00 PM on Friday, May 29th. If you are interested in attending, please visit the registration desk outside Continental Room B (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Faculty

Faculty

Sarah B Goldberg

MD, MPH

Yale Cancer Center, New Haven, Connecticut

Professor of Medicine (Medical Oncology), Chief of Thoracic Oncology

Faculty

Jonathan Goldman

MD

UCLA Health, Santa Monica, California

Professor of Medicine, UCLA Hematology and Oncology, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development

Faculty

Joel W Neal

MD, PhD

Stanford University School of Medicine, Palo Alto, California

Lead, Thoracic Oncology Clinical Research Group/Cancer Care Program Professor of Medicine, Division of Oncology

Moderator

Jacob Sands

MD

Dana-Farber Cancer Institute, Boston, Massachusetts

Associate Chief, Thoracic Oncology

Harvard Medical School, Boston, Massachusetts

Assistant Professor

Faculty

Antonio Passaro

MD, PhD

European Institute of Oncology, Milan, Italy

Director, Division of Thoracic Oncology

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:30 PM — Educational Meeting

MODULE 1: Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

• Long-term outcomes observed with up-front osimertinib monotherapy for patients with metastatic EGFR-mutated NSCLC
• Major efficacy and safety findings, including outcomes from the final overall survival (OS) analysis, from the Phase III FLAURA2 trial of osimertinib combined with chemotherapy versus osimertinib alone as first-line treatment for EGFR-mutant NSCLC
• Extended follow-up, including published OS findings, from the Phase III MARIPOSA trial of up-front treatment with amivantamab/lazertinib or lazertinib alone versus osimertinib for patients with metastatic EGFR-mutant NSCLC
• Documented CNS activity of osimertinib/chemotherapy and amivantamab/lazertinib in EGFR-mutated advanced NSCLC
• Optimal selection of patients with newly diagnosed EGFR-mutated NSCLC to receive osimertinib/chemotherapy and amivantamab/lazertinib

MODULE 2: EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC

• Key data from the Phase III MARIPOSA-2 study supporting the FDA approval of amivantamab in combination with platinum-based chemotherapy for patients with progressive EGFR-mutated advanced NSCLC
• Optimal incorporation of amivantamab/chemotherapy into current management algorithms
• Efficacy and safety outcomes documented with a subcutaneous formulation of amivantamab in combination with lazertinib in refractory and treatment-naïve EGFR-mutated advanced NSCLC
• Available findings from the COMPEL trial comparing platinum-based chemotherapy with and without osimertinib for patients with EGFR-mutated advanced NSCLC and non-CNS disease progression on first-line osimertinib
• Early data with and ongoing studies combining osimertinib with other systemic therapies in order to overcome common mechanisms of resistance

MODULE 3: Utility of TROP2-Targeted Antibody-Drug Conjugates (ADCs) in the Management of EGFR-Mutant NSCLC

• Mechanism of antitumor activity of datopotamab deruxtecan (Dato-DXd) and rationale for its investigation in pretreated EGFR-mutant NSCLC
• Antitumor activity observed with Dato-DXd in patients with previously treated EGFR-mutated NSCLC in a pooled analysis of the TROPION-Lung05 and TROPION-Lung01 trials
• Recent FDA approval of Dato-DXd for EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy; current role of this strategy
• Intracranial activity of Dato-DXd in patients with NSCLC and brain metastases; implications for its utility in pretreated EGFR-mutant disease
• Published data with and ongoing evaluation of other TROP2-targeted antibody-drug conjugates (eg, sacituzumab tirumotecan) for EGFR TKI-resistant, EGFR-mutated advanced NSCLC

MODULE 4: Emerging Role of Bispecific Antibody-Based Approaches in the Treatment of EGFR-Mutated NSCLC

• Available data with and current role, if any, of immune checkpoint inhibitors in therapy for patients with NSCLC and EGFR mutations
• Mechanism of antitumor activity of the PD-1 x VEGF bispecific antibody ivonescimab; rationale for its investigation in pretreated EGFR-mutant NSCLC
• Design, eligibility criteria and efficacy and safety findings from the Phase III HARMONi trial evaluating ivonescimab in combination with carboplatin and pemetrexed for patients with EGFR-mutated NSCLC after disease progression on a third-generation TKI
• Recent acceptance of a biologics license application for ivonescimab/chemotherapy for pretreated EGFR-mutated NSCLC; potential role in clinical practice
• Structural components and mechanism of action of the first-in-class bispecific antibody-drug conjugate izalontamab brengitecan (iza-bren)
• Available research data with and ongoing evaluation of iza-bren for patients with NSCLC harboring EGFR mutations

MODULE 5: Tolerability Considerations with Available and Emerging Therapies for NSCLC with EGFR Mutations

• Comparative tolerability profiles of osimertinib/chemotherapy and amivantamab/lazertinib; implications for the selection of first-line therapy for EGFR-mutant metastatic NSCLC
• Optimal approach to preventing infusion-related reactions with amivantamab; relevant findings from the Phase II SKIPPirr study
• Results from the Phase II COCOON study evaluating the impact of enhanced versus standard dermatologic management on the incidence of dermatologic adverse events (AEs) for patients with EGFR-mutated metastatic NSCLC who receive first-line amivantamab/lazertinib
• Spectrum, frequency and severity of toxicities reported with Dato-DXd for patients with EGFR-mutant advanced NSCLC
• Recommended algorithms for monitoring for, mitigating and managing common and more serious AEs documented with Dato-DXd
• Frequency, severity and management of toxicities associated with ivonescimab

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to 

• Counsel patients with newly diagnosed metastatic EGFR-mutated non-small cell lung cancer (NSCLC) regarding available therapeutic considerations, explaining the relevance of mutation type, symptomatology, sites and extent of metastases, prior therapeutic exposure and other factors.
• Appreciate the biological rationale for dual inhibition of MET and EGFR for patients with EGFR-mutated NSCLC, and understand recently presented data establishing the benefit of this strategy.
• Evaluate the documented efficacy of chemotherapy combined with EGFR-targeted therapy, and consider the current role of available approaches in both the front-line and relapsed/refractory settings for patients with metastatic NSCLC and EGFR mutations.
• Review published research findings with TROP2-directed antibody-drug conjugates for patients with metastatic NSCLC and EGFR mutations, and optimally incorporate these agents into treatment algorithms.
• Appraise the scientific rationale for the development of bispecific antibodies directed at PD-1 x VEGF, and reflect on the potential role of these agents in the management of EGFR-mutated NSCLC.
• Recall the biological rationale for the evaluation of various novel therapeutic approaches for patients with NSCLC and EGFR mutations.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — Prof Passaro has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Goldberg — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BlossomHill Therapeutics, Daiichi Sankyo Inc, Johnson & Johnson, Lilly, Merck, Regeneron Pharmaceuticals Inc, Summit Therapeutics, Synthekine, Tubulis; Contracted Research: Adela, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Mirati Therapeutics Inc; Data and Safety Monitoring Boards/Committees: Daiichi Sankyo Inc. Dr Goldman — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pfizer Inc, Summit Therapeutics; Contracted Research: AbbVie Inc, Agenus Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, RayzeBio, Summit Therapeutics, Tango Therapeutics. Dr Neal — Advisory Committees (Consulting and Advisory): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Iovance Biotherapeutics, Janssen Biotech Inc, Lilly, Natera Inc, Novartis, Novocure Inc, Nuvation Bio Inc, Oxford BioTherapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Summit Therapeutics, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Adaptimmune, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Lilly, Merck, Novartis, Nuvalent, Revolution Medicines Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Stock Options/Stock — Public Companies: SecondLook Health.

MODERATOR
Dr Sands — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Catalyst Pharmaceuticals Inc, Daiichi Sankyo Inc, Fosun Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Lilly, Merck, Novartis, Pfizer Inc, PharmaMar, Sanofi; Contracted Research: Amgen Inc, Novartis.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Johnson & Johnson.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room A (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:00 PM on Friday, May 29th. If you are interested in attending, please visit the registration desk outside Continental Room A (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.